Study Enrollment

Your details will not be published or shared.

Clinical Trial

Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life: A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents (SUMMIT)

This prospective, observational study will help to better understand the evolving real-world treatment outcomes (including treatment patterns, reasons for discontinuation/dose reduction, treatment interruption or treatment switches), physician-reported clinical outcomes, and patient-reported symptoms and health-related quality of life (HRQoL) among patients diagnosed with mantle cell lymphoma (MCL) who newly initiated a novel therapy in the past 3 months, and treatment is ongoing at the time of enrollment.

Eligibility Criteria

  • Inclusion Criteria Patients diagnosed with MCL Informed consent for participation Age greater than or equal to18 years old, as of the first observed diagnosis of MCL Patients for whom a clinical decision has been made to initiate novel therapy in the last 3 months, limited to the novel agent categories in Table 1. The novel agent must have been granted approval in at least one hematological cancer. Treatment must be ongoing at the time of enrollment. Exclusion Criteria Patients will be excluded from study participation if they are enrolled in clinical studies that prohibit any participation in this non-interventional study, or clinical studies where treatment is blinded (participation in open-label studies is permitted if approved by the site Investigator) at the time of informed consent.

Contact Information

    Gita Giddens

    (706) 721-1374